Everpure (NYSE:P – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $130.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 18.66% from the company’s current price. Several […]

Nuvation Bio (NYSE:NUVB – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $11.00 price target on the stock. Wedbush’s target price would suggest a potential upside of 89.82% from the company’s current price. A […]